Sort   by:  
 Page size 
TranscriptomicsNASH
Non-alcoholic fatty liver disease (NAFLD) is characterized by a series of pathological changes that can progress from simple fatty liver disease to non-alcoholic steatohepatitis (NASH). The objective of this study is to describe changes in global gene expression associated with the progression of NA...
ORGANISM(S): Homo sapiens 
2011-07-12 | E-MEXP-3291 | biostudies-arrayexpress
TranscriptomicsExpression data from mouse liver treated with metformin
Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes. We examined the effects of metformin, commonly used to treat patients with type 2 diabetes, on liver pathology in a non-diabetic NASH mouse model. Eight-week-old C57...
ORGANISM(S): Mus musculus 
2012-02-21 | E-GEOD-35961 | biostudies-arrayexpress
MetabolomicsDeficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease
Non-alcoholic fatty liver is the most common liver disease worldwide. Here, we show that the mitochondrial protein mitofusin 2 (Mfn2) protects against liver disease. Reduced Mfn2 expression was detected in liver biopsies from patients with non-alcoholic steatohepatitis (NASH). Moreover, reduced Mfn2...
2018-01-25 | MTBLS600 | MetaboLights
ProteomicsmARC1 knockdown protects liver from diet-induced NASH in mouse
Human genetic studies have identified several MARC1 variants as protective against non-alcoholic fatty liver diseases (NAFLD). The MARC1 variants are associated with reduced lipid profiles, liver enzymes, and liver-related mortality. However, the role of mitochondrial amidoxime reducing component 1 ...
ORGANISM(S): Mus Musculus (ncbitaxon:10090) 
2023-04-28 | MSV000091820 | MassIVE
MetabolomicsDT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates

Nonalcoholic steatohepatitis (NASH) prevalence is rising with no pharmacotherapy approved. A major hurdle in NASH drug development is the poor translatability of preclinical studies to safe/effective clinical outcomes, and recent failures highlight a need to identify new targetable pathways. Dysr...

2023-04-13 | MTBLS5005 | MetaboLights
ProteomicsPD-1-targeted immunotherapy in NASH-triggered liver cancer induces pro-tumorigenic environment through CD8+PD-1+ T-cells
Immunotherapy has opened hitherto unknown possibilities to treat cancer. Whereas some cancer types (e.g. melanoma) can be efficiently treated, others lack measurable positive effects (e.g. PDAC). Moreover, stratification of responders/non-responders is only possible in some cancer types (e.g. melano...
ORGANISM(S): Mus musculus (Mouse) 
2021-03-03 | PXD017236 | Pride
Immunotherapy Cd8+pd1+ Nash 
TranscriptomicsGene expression profiles of livers and liver tumors from mice fed high-fat diet and high fructose-glucose solution for 52 weeks
The lack of a preclinical model of nonalcoholic steatohepatitis (NASH) and hepatocellular cancer (HCC) that recapitulates human disease is a major barrier to therapeutic development. We report a high fat-high sugar diet-induced NASH and HCC in a stable isogenic 129S1/SvImJ crossed with C57Bl/6J mice...
ORGANISM(S): Mus musculus 
2016-07-25 | E-GEOD-67679 | biostudies-arrayexpress
TranscriptomicsGene expression profiles of livers from mice fed high-fat diet and high fructose-glucose solution for 8 weeks
The lack of a preclinical model of nonalcoholic steatohepatitis (NASH) and hepatocellular cancer (HCC) that recapitulates human disease is a major barrier to therapeutic development. We report a high fat-high sugar diet-induced NASH and HCC in a stable isogenic 129S1/SvImJ crossed with C57Bl/6J mice...
ORGANISM(S): Mus musculus 
2016-07-25 | E-GEOD-67678 | biostudies-arrayexpress
UnknownpNaKtide Attenuates Steatohepatitis and Atherosclerosis by Blocking Na/K-ATPase/ROS Amplification in C57Bl6 and ApoE Knockout Mice Fed a Western Diet.
Not available
S-EPMC5428305 | biostudies-literature
ProteomicsAmelioration of nonalcoholic fatty liver disease by inhibiting the deubiquitylating enzyme RPN11
Nonalcoholic fatty liver disease (NAFLD) including its more severe manifestation, nonalcoholic steatohepatitis (NASH), is a global public health challenge. Here, we reveal a role for the deubiquitinating enzyme RPN11 in the development of NAFLD and NASH. Ablation of hepatic RPN11 markedly protected ...
ORGANISM(S): Homo Sapiens Mus Musculus 
2024-06-15 | PXD053163 |
Sort   by:  
 Page size